Comparison
While Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768, LL-37 acts as a broad-spectrum antimicrobial and immunomodulatory peptide involved in host defense and wound repair, but can also promote inflammation and cancer cell proliferation in some contexts5215.
While Exenatide works as a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67, LL-37 is a cationic amphipathic 37-amino-acid cathelicidin peptide generated from hCAP18 that disrupts microbial membranes and modulates innate immunity, including chemotaxis, cytokine induction, and NET formation521586.
Exenatide is 39 amino acids long, whereas LL-37 is shorter as it has a length of 37 amino acids. Exenatide is made up of a sequence of sequence data not available in the current dataset. LL-37 is made up of a sequence of Leucine, Leucine, Glycine, Aspartic acid, Phenylalanine, Phenylalanine, Arginine, Lysine, Serine, Lysine, Glutamic acid, Lysine, Isoleucine, Glycine, Lysine, Glutamic acid, Phenylalanine, Lysine, Arginine, Isoleucine, Valine, Glutamine, Arginine, Isoleucine, Lysine, Aspartic acid, Phenylalanine, Leucine, Arginine, Asparagine, Leucine, Valine, Proline, Arginine, Threonine, Glutamic acid, Serine.
Exenatide
Not assigned in the current dataset.
LL-37
CAMP